ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 12| December 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

DETAIL REVIEW ON DRUG REGULATORY AFFAIRS

Shreyash G. Sallawar[1], Dr. Sunil S. Jaybhaye[2], Mr. Kshitijkumar G.Wagh[3]
Institute of Pharmacy, Badnapur

ABSTRACT

Drug Regulatory Affairs (DRA) is a vital and multidisciplinary field within the pharmaceutical industry that ensures the safety, efficacy, and quality of medicinal products throughout their life cycle. It involves the systematic management of all regulatory requirements associated with the research, development, manufacturing, marketing authorization, and postmarketing activities of drugs. The primary objective of DRA is to safeguard public health by ensuring that pharmaceutical products meet the necessary scientific, ethical, and legal standards established by national and international regulatory authorities. Major agencies such as the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), the Central Drugs Standard Control Organization (CDSCO) in India, and the World Health Organization (WHO) play key roles in regulating and monitoring these processes globally.

Regulatory affairs professionals act as the interface between pharmaceutical companies and regulatory bodies, facilitating the preparation and submission of documents like Investigational New Drug (IND) applications, New Drug Applications (NDA), and Marketing Authorization Applications (MAA). They also ensure continuous compliance through postapproval activities such as pharmacovigilance, product variation submissions, and labelling updates. With the increasing globalization of the pharmaceutical market, harmonization of regulatory guidelines through organizations such as the International Council for Harmonisation (ICH) has become essential. Therefore, Drug Regulatory Affairs serves as the backbone of modern drug development, ensuring that safe, effective, and high-quality medicines reach patients worldwide.

INTRODUCTION

Drug Regulatory Affairs (DRA) is a crucial discipline in the pharmaceutical industry that ensures all drugs meet the required standards of safety, efficacy, and quality before reaching patients. It involves compliance with national and international regulations set by authorities such as the FDA, EMA, and CDSCO. Professionals in this field manage the preparation, submission, and maintenance of regulatory documents for drug approval, licensing, and post-marketing activities. With the continuous evolution of global health standards, DRA plays a vital role in bridging scientific innovation and public health protection, ensuring that new medicines are developed, approved, and marketed responsibly and ethically.

History of Drug Regulatory Affairs

The history of Drug Regulatory Affairs (DRA) traces back to the early efforts to ensure the safety and quality of medicines. In the 19th century, the lack of regulation led to widespread use of unsafe and adulterated drugs. This prompted governments to establish laws to protect public health. One of the earliest examples was the Pure Food and Drugs Act (1906) in the United States, which marked the beginning of formal drug regulation.

Following major drug-related tragedies—such as the sulfanilamide disaster (1937) and the thalidomide tragedy (1961)—stricter laws were introduced worldwide to ensure drug safety, efficacy, and proper testing before marketing. These events led to the creation and strengthening of major regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

In India, the Drugs and Cosmetics Act of 1940 established a legal framework for drug regulation under the Central Drugs Standard Control Organization (CDSCO). Over time, globalization and technological advances led to the development of international harmonization initiatives, such as the International Council for Harmonisation (ICH), to standardize regulatory requirements across countries. data integrity and lifecycle management.

ROLE AND NEED OF DRUG REGULATORY AFFAIRS

Role

Drug Regulatory Affairs (DRA) plays a crucial role in ensuring that pharmaceutical products are developed, manufactured, and marketed according to legal and scientific standards. The primary role of DRA professionals is to act as a bridge between pharmaceutical companies and regulatory authorities. They prepare, submit, and maintain documents required for drug approval, such as Investigational New Drug (IND) applications, New Drug Applications (NDA), and post-marketing reports. DRA also ensures compliance with global regulations, labelling requirements, and quality standards throughout the product's life cycle.

Need

The need for Drug Regulatory Affairs arises from the growing complexity of drug development and the necessity to protect public health. With diverse regulatory frameworks across countries, DRA ensures that all safety, efficacy, and quality standards are met before a drug reaches patients. It helps

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 12| December 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

companies avoid legal issues, accelerates market access, and maintains consistent product quality. Moreover, as globalization and innovation in pharmaceuticals increase, effective regulatory affairs are essential to harmonize standards, manage risks, and ensure timely availability of safe and effective medicines worldwide.

Dossier Preparation in CTD Format and eCTD Submissions

In drug regulatory affairs, dossier preparation is a crucial step for obtaining approval to market a new drug. A dossier is a comprehensive document that contains all scientific, technical, and administrative information about a pharmaceutical product. To standardize global submissions, regulatory authorities have adopted the Common Technical Document (CTD) format, developed by the International Council for Harmonisation (ICH).

Common Technical Document (CTD) Format

The CTD organizes the data into five well-defined modules:
Administrative Information and Product Information:
Contains region-specific administrative data such as application forms, labelling, and prescribing information.
Common Technical Document Summaries:
Provides summaries and overviews of the quality, non-clinical, and clinical information. Quality (Chemistry, Manufacturing, and Controls):
Includes details about drug substance and product—such as manufacturing process, specifications, and stability data.
Non-clinical Study Reports:
Contains pharmacology, pharmacokinetics, and toxicology study reports conducted on animals.
Clinical Study Reports:
Comprises data from human clinical trials, including bioavailability, efficacy, and safety results.
The CTD format allows consistency and facilitates review by multiple regulatory authorities, reducing duplication of efforts.

Electronic Common Technical Document (eCTD)

The eCTD is the electronic version of the CTD that enables online submission, review, and lifecycle management of drug applications. It ensures a paperless, efficient, and traceable submission process.

Key Features of eCTD

Structured using XML backbone files for easy navigation.
Allows updates, amendments, and tracking through version control.
Accepted by major authorities such as the US FDA, EMA, PMDA (Japan), and CDSCO (India).

Advantages of eCTD Submissions

Streamlines regulatory review and approval timelines.
Reduces physical paperwork and cost.
Facilitates easy data retrieval and global harmonization.
Improves Role in Drug Regulatory Affairs
Regulatory professionals are responsible for:
Compiling, formatting, and validating CTD/eCTD dossiers.
Ensuring compliance with each region's technical specifications.
Coordinating between R&D, manufacturing, and clinical teams.
Managing submissions, updates, and communication with regulatory bodies.

Introduction to Current Good Manufacturing Practices (cGMP)

Current Good Manufacturing Practices (cGMP) are a set of regulations, codes, and guidelines established by regulatory authorities to ensure that pharmaceutical products, medical devices, and food items are consistently produced and controlled according to quality standards. The main objective of cGMP is to ensure product safety, efficacy, and quality for consumer use.
These practices cover all aspects of production — from the starting materials, equipment, and facilities to the training and hygiene of staff. Detailed written procedures are essential for each process that could affect the quality of the final product. Proper documentation and record-keeping are crucial to demonstrate compliance with these standards.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA), World Health Organization (WHO), European Medicines Agency (EMA), and Central Drugs Standard Control Organization (CDSCO) in India enforce cGMP requirements. The "current" in cGMP emphasizes the need for manufacturers to use up-to-date technologies and systems to comply with the latest quality standards.
In essence, cGMP ensures that medicines and health products are safe, effective, and of the highest possible quality, protecting public health and maintaining consumer confidence.

Today, Drug Regulatory Affairs has evolved into a specialized global profession, ensuring that every medicinal product undergoes thorough evaluation for quality, safety, and efficacy before reaching the public
Here's a well-organized and academic-style explanation for your Drug Regulatory Affairs topic on Compliance Guidelines, Government Audits, and Breach Reports, covering the major authorities (FDA, MHRA, PMDA, TGA, CDSCO).

Compliance Guidelines, Government Audits, and Breach Reports

Compliance Guidelines

Compliance guidelines ensure that pharmaceutical companies follow legal, ethical, and scientific standards during drug development, manufacturing, and marketing. These guidelines are established by regulatory authorities to maintain product quality, patient safety, and data integrity. Key areas include:
Good Manufacturing Practices (GMP)
Good Clinical Practices (GCP)
Good Laboratory Practices (GLP)
Pharmacovigilance and Risk Management
Data Integrity and Record Management

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 12| December 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

Adherence to these ensures that all operations are transparent, validated, and traceable.

U.S. FDA (Food and Drug Administration)
Conducts GMP inspections to ensure manufacturing facilities meet quality standards.
Evaluates clinical trial data, marketing authorization applications, and pharmacovigilance systems.
Issues Form 483 for observations and Warning Letters for serious non-compliance.

MHRA (Medicines and Healthcare Products Regulatory Agency, UK) Audits are focused on GxP compliance (GMP, GCP, GLP).
Performs risk-based inspections of manufacturing sites and clinical trial sponsors. Ensures data integrity and product traceability within the UK regulatory framework.

PMDA (Pharmaceuticals and Medical Devices Agency, Japan)
Ensures products meet Japanese Pharmaceutical and Medical Device Act standards.
Conducts pre-approval, periodic, and foreign inspections.
Works with MHLW (Ministry of Health, Labour and Welfare) for product licensing.

CDSCO (Central Drugs Standard Control Organization, India)
The National Regulatory Authority under the Ministry of Health & Family Welfare.
Regulates clinical trials, drug import/export, manufacturing, and marketing authorization
Conducts periodic inspections through Zonal Offices and issues show-cause notices for violations.



Breach Reports
A breach occurs when a company violates compliance standards, regulations, or fails to report critical data. Breaches can include:
Data falsification or manipulation
Non-conformance with GMP
Adverse event underreporting
Unauthorized product changes
Regulatory authorities require companies to report breaches immediately, followed by Corrective and Preventive Actions (CAPA). Failure to do so may result in:
Product recalls
Suspension of manufacturing licenses
Financial penalties or legal action

Regulatory Framework in India
In India, biologics are regulated by the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940 and New Drugs and Clinical Trials Rules, 2019. Marketing authorization is granted by the Drug Controller General of India (DCGI) after review of preclinical and clinical data submitted in CTD format. For similar biologics (biosimilars), CDSCO issued guidelines in 2022 requiring comparability studies. Labelling follows the Drugs and Cosmetics Rules, which specify essential information such as composition, batch number, and storage instructions.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 12| December 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

Regulatory Framework in the United States

In the USA, biologics are controlled by the Food and Drug Administration (FDA) under the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. A biologic must obtain approval through a Biologics License Application (BLA) following successful Investigational New Drug (IND) trials. Labelling is regulated under 21 CFR Part 201, which requires standardized prescribing information and patient leaflets.

Regulatory Framework in Europe

The European Medicines Agency (EMA) governs biologics under Regulation (EC) No. 726/2004. Most biologics are approved through the centralized procedure, which grants marketing authorization across all EU countries. Labelling must comply with EU directives and includes the Summary of Product Characteristics (SmPC), Package Leaflet (PL), and outer labelling.

CONCLUSION

While all three regions share the goal of ensuring the safety and efficacy of biologics, their regulatory approaches vary in structure and format. India follows CDSCO rules, the USA uses the FDA's BLA process, and Europe relies on EMA's centralized authorization. Despite procedural differences, these systems collectively uphold global standards for biologic drug quality and labelling.

Vaccine Regulations — India, USA, European Union

CDSCO (India) — Vaccine Policy, NDCTR 2019, CDSCO vaccine pages and pharmacovigilance guidance.
FDA / CBER (USA) — vaccine pages, development & approval process, safety surveillance.
EMA (EU) — clinical evaluation guideline for vaccines, marketing-authorisation and RMP/pharmacovigilance guidance.

Clinical evaluation

India (CDSCO)

Vaccines are developed and evaluated under the NDCTR (2019) and CDSCO vaccine guidance; clinical programmes must show safety, immunogenicity and efficacy with appropriate age/target-group studies. Pre-submission interactions with CDSCO are recommended. Emergency/restricted use pathways have separate guidance used (e.g., for COVID-19 vaccines).

USA (FDA/CBER)

Clinical development follows IND → phased clinical trials (Phase I–III). FDA/CBER evaluates safety, immunogenicity and efficacy endpoints; sponsors can request pre-IND and biologics meetings. For public-health emergencies, Emergency Use Authorization (EUA) can allow earlier access subject to evidence and conditions.

EU (EMA)

EMA's clinical evaluation guideline sets a stepwise approach: immunogenicity, safety and clinical efficacy/endpoints; special guidance for adjuvanted vaccines, changes and paediatric/elderly populations. Scientific advice from EMA is strongly recommended.

Marketing authorization / Registration / Licensing

India

Marketing authorisation (MA) granted by CDSCO/DCGI after local review of CTD dossier. For products already authorised abroad, CDSCO may offer accelerated/restricted routes under specified conditions. Lot release and licensing of manufacturing sites are required.

USA

Full approval via Biologics License Application (BLA). FDA inspects manufacturing sites (GMP) and reviews full CMC, nonclinical and clinical data. EUA is a temporary option during emergencies.

EU

Most human vaccines use the centralised marketing-authorisation procedure (one MAA through EMA → EU-wide MA). Conditional marketing authorisations (CMAs) may be granted where immediate benefit outweighs remaining uncertainties .

Quality assessment (CMC, manufacturing & lot release)

India

Detailed Module-3 (CTD) requirements, manufacturing process description, characterization, stability, and batch/lot release are required. India uses national lot-release laboratories (e.g., CDL) for independent testing of vaccine lots. GMP inspections of facilities required for licensing.

USA

FDA conducts a thorough CMC review in the BLA: manufacturing controls, potency assays, stability, container/closure and sterility. FDA inspects manufacturing facilities and may set specific lot-release/testing requirements.

EU

EMA expects a complete CMC package in the CTD (Module 3). GMP compliance and batch certification/lot release are required; national or EU-level testing and quality oversight apply before distribution.

Pharmacovigilance (Post-Marketing Safety Monitoring)

India

India runs an AEFI (Adverse Events Following Immunization) program and MAHs must maintain PV systems, report ICSRs/AEFIs, submit PSURs/PBRERs and perform postmarketing studies when requested. CDSCO published vaccine-specific PV guidance.

USA

FDA/CDC use passive (VAERS) and active surveillance systems and require post-marketing commitments, periodic safety reports

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 12| December 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

and post-authorization studies; CBER coordinates vaccine safety monitoring.

EU
EMA requires a Risk Management Plan (RMP) with MAAs, PSURs and comprehensive PV systems; EMA coordinates EU-wide pharmacovigilance and safety signal management.
Additional / special requirements :
Lot release & independent testing: India uses national lot-release labs; FDA and EU may require specific batch testing or allow reliance on manufacturer release supported by regulatory oversight.

Cold chain & distribution: All jurisdictions enforce cold-chain requirements via labelling and GMP/GDP expectations; specifics are product dependent. (See national guidance & manufacturer instructions.)

Accelerated / emergency pathways:
USA (EUA), EU (Conditional MA), India (restricted/emergency use approvals) — each has defined evidentiary and duration/monitoring conditions.

Regulatory interactions: Pre-submission scientific advice (EMA), pre-IND/Type B meetings (FDA), and CDSCO pre-submission meetings are recommended to de-risk programs.

Here's a clear, structured explanation of Regulatory Requirements for Registration of Drugs, Medical Devices, and Post-Approval Requirements in WHO, suitable for your Drug Regulatory Affairs notes or research paper:

Regulatory Requirements for Registration of Drugs, Medical Devices, and PostApproval Requirements in WHO
Introduction
The World Health Organization (WHO) plays a vital role in ensuring the quality, safety, and efficacy of pharmaceuticals and medical devices globally. Although WHO itself does not grant marketing authorization, it provides international standards, guidelines, and a prequalification program to assist countries and manufacturers in regulatory compliance.

Drug Registration under WHO Guidelines:
WHO assists member countries and manufacturers through the WHO Prequalification Programme (PQP), ensuring products meet global quality standards.

Key Steps
Application Submission
Manufacturer submits a dossier in CTD (Common Technical Document) format.
Includes data on quality (CMC), safety, efficacy, and GMP compliance.

Assessment
WHO experts evaluate documentation.
Assessment follows ICH and WHO guidelines for analytical validation and clinical performance.

Inspection
WHO conducts Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) inspections.

Prequalification Decision
If compliant, product is listed on the WHO prequalified list, used by UN agencies and countries for procurement.

Medical Device Registration under WHO
The WHO does not directly approve devices but provides a Global Model Regulatory Framework for Medical Devices to guide national regulatory authorities.
Essential Elements
Device classification: Based on risk (Class A–D).
Quality Management System: ISO 13485 compliance.
Technical Documentation: Device description, design, risk analysis, and clinical evidence.
Conformity Assessment: May involve third-party audits.
Labelling and Post-market Surveillance: Must comply with WHO and IMDRF (International Medical Device Regulators Forum) recommendations.

Post-Approval (Post-Market) Requirements
After prequalification or registration, products are continuously monitored to ensure safety and performance.

Post-Approval Obligations
Pharmacovigilance / Vigilance System
Ongoing collection and analysis of adverse events.
Manufacturers must report serious adverse events to WHO and relevant authorities.

Periodic Safety Update Reports (PSURs)
Regular submission of updated safety and efficacy data.

Renewal / Requalification
WHO prequalified status must be maintained through requalification every few years or after significant changes.

Variation or Change Control
Any changes in manufacturing, formulation, or labelling require prior notification and approval.

WHO's Role in Harmonization
WHO collaborates with regional organizations (like ICH, IMDRF, and African Medicines Agency) to harmonize regulatory standards.
Provides training, capacity building, and technical assistance to national regulatory agencies.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 12| December 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188



CONCLUSION

Central role: Start by stating that drug regulatory affairs (DRA) is an indispensable function that ensures pharmaceutical products meet the highest standards of safety, quality, and efficacy.
Bridge between industry and government: Emphasize that DRA professionals act as the essential interface between pharmaceutical companies and regulatory authorities, managing the communication and documentation required for approval.

Importance of compliance: Stress that navigating the complex and ever-changing landscape of international and national regulations is paramount for a company's success and for protecting public health.

Lifecycle involvement: Conclude by reinforcing that involvement from regulatory affairs is necessary throughout the entire drug lifecycle, from the initial phases of research and development through post-market surveillance.

Forward-looking statement: Briefly mention the future, such as the growing importance of real-time data, AI, and patient-reported outcomes in post-market surveillance to ensure continued safety and efficacy, according to Skill bee Solution.

REFERENCES

1.Drug Regulatory Affairs — Regulatory Sciences
Author: Javed Ali, Shailendra Saraf
Publisher: CBS Publishers
2.Pharmaceutical Regulatory Affairs: Fundamentals and Future
Author: Regulatory Affairs Professionals Society (RAPS)
Publisher: RAPS

3.Comprehensive Guide to Drug Regulatory Affairs
Author: G. Vidya Sagar

4.Pharmaceutical Regulatory Affairs
Author: C.V.S. Subrahmanyam
ICH Q1–Q14 (Quality, Safety, Efficacy, M4 CTD)

Website: ICH Official Portal
WHO Guidelines
WHO Technical Report Series (TRS)
WHO Regulatory Guidance for Medicines

US FDA
Code of Federal Regulations (21 CFR)
Guidance for Industry – FDA
Drugs@FDA database
EMA (Europe)
EMA Scientific Guidelines
EudraLex Volume 1–10

MHRA (UK)
Guidance on licensing medicines
MHRA Orange Guide
PMDA (Japan)
Pharmaceuticals and Medical Devices Agency Review Reports
CDSCO (India)
New Drugs and Clinical Trials Rules (NDCTR), 2019
CDSCO guidelines for import, manufacturing, approval

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 12| December 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

"Overview of Drug Regulatory Affairs" Journal of Pharmaceutical Sciences
"Global Regulatory Framework for Drug Development" International Journal of Drug Development & Research
"Role of WHO in Global Drug Regulation" WHO Bulletin
"CTD & eCTD: A Global Submission Format" Regulatory Affairs Journal Pharma
Drug Controller General of India.
Indian Pharmacopoeia Commission.